Clinical Trial Detail

NCT ID NCT01990196
Title Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer
Recruitment Active, not recruiting
Gender male
Phase Phase II
Variant Requirements No
Sponsors Jonsson Comprehensive Cancer Center
Indications

prostate cancer

Therapies

Dasatinib

Trametinib

Degarelix + Enzalutamide

Age Groups: adult

No variant requirements are available.